Frank Follmann

Title: Frank Follmann: Innovator in Vaccine Development

Introduction

Frank Follmann is a notable inventor based in Soborg, Denmark. He has made significant contributions to the field of vaccine development, holding two patents that showcase his innovative approach to immunology.

Latest Patents

Follmann's latest patents focus on vaccines against Chlamydia trachomatis (Ct). The first patent describes an efficient vaccine based on recombinant fusion molecules that generate a high titered neutralizing antibody response, providing protection against various Ct serovars. This invention aims to activate both arms of the immune system by combining antibody-promoting fragments with Ct antigens that target T cells. The second patent relates to antigens recognized by specific antibodies from individuals infected with Ct, which can induce T cells to secrete gamma-interferon. These T cell reactive antigens are present in a whole-cell lysate and have molecular weights ranging from 5-12 kDa to 58-74 kDa, as determined by SDS-PAGE. The antigens are believed to be useful not only in vaccines but also as diagnostic compositions.

Career Highlights

Frank Follmann is associated with the Statens Serum Institut, where he continues to advance his research in vaccine development. His work has the potential to significantly impact public health by providing effective immunization strategies against infectious diseases.

Collaborations

Follmann collaborates with esteemed colleagues, including Anja Olsen and Peter Andersen, who contribute to his research endeavors.

Conclusion

Frank Follmann's innovative work in vaccine development highlights his commitment to advancing medical science. His patents reflect a deep understanding of immunology and a dedication to improving health outcomes through effective vaccination strategies.